Ionis' Tryngolza Claims Critical Label Expansion in US

Ionis' Tryngolza claims critical label expansion in US

Ionis' Tryngolza has been approved for severe hypertriglyceridaemia, opening the door to what the company thinks could be a $3bn market opportunity.

Ionis wins FDA label expansion for potential blockbuster triglycerides indication

Ionis landed an FDA approval on Wednesday that will greatly expand its commercial opportunity for Tryngolza. The antisense drug may now be used to treat patients who have severely high levels of fat molecules called ...